This inhibition disrupts VEGF binding to vascular endothelial growth factor receptor (VEGFR) on the surface of vascular endothelial cells, leading to the suppression of tumor angiogenesis, growth, and metastasis, making it an efficient anti-tumor agent. The gene discussed is KDR; the disease is neoplasm.